Table 2 Clinical characteristics and metabolic markers of subjects.
Clinical indication | underweight people (n = 57) | Normal range (n = 883) | overweight people (n = 731) | p value |
|---|---|---|---|---|
Age (year) | 21–67 | 19–93 | 20–88 | <0.0001 |
Gender (Male/Female) | 12/45 | 335/548 | 544/187 | <0.0001 |
BMI | 17.62 ± 0.73 | 22.29 ± 1.73 | 27.92 ± 2.56 | <0.0001 |
WBC (*109/L) | 5.59 ± 1.39 | 5.93 ± 1.43 | 6.53 ± 1.54 | <0.0001 |
RBC (*1012/L) | 4.58 ± 0.38 | 4.68 ± 0.46 | 5.01 ± 0.43 | <0.0001 |
HGB (g/L) | 135.02 ± 16.29 | 138.88 ± 17.18 | 150.32 ± 14.58 | <0.0001 |
PLT (*109/L) | 263.82 ± 55.52 | 263.59 ± 60.56 | 263.38 ± 58.79 | 0.9967 |
NEU (*109/L) | 3.25 ± 1.10 | 3.47 ± 1.11 | 3.79 ± 1.13 | <0.0001 |
LYM (*109/L) | 1.91 ± 0.53 | 1.97 ± 0.53 | 2.17 ± 0.64 | <0.0001 |
MONO (*109/L) | 0.30 ± 0.09 | 0.33 ± 0.11 | 0.38 ± 0.11 | <0.0001 |
EOS (*109/L) | 0.10 ± 0.07 | 0.13 ± 0.12 | 0.16 ± 0.15 | <0.0001 |
BAS (*109/L) | 0.03 ± 0.01 | 0.03 ± 0.02 | 0.03 ± 0.02 | 0.0002 |
NEU% | 57.32 ± 8.18 | 57.89 ± 7.93 | 57.61 ± 7.54 | 0.7082 |
LYM% | 34.82 ± 8.03 | 33.73 ± 7.37 | 33.59 ± 7.18 | 0.4779 |
MON% | 5.53 ± 1.28 | 5.65 ± 1.45 | 5.87 ± 1.42 | 0.0018 |
EOS% | 1.84 ± 1.17 | 2.21 ± 1.90 | 2.42 ± 1.99 | 0.0103 |
BAS% | 0.50 ± 0.23 | 0.51 ± 0.28 | 0.51 ± 0.28 | 0.9242 |
TC (mmol/L) | 4.46 ± 0.84 | 4.74 ± 0.91 | 4.95 ± 0.90 | <0.0001 |
TG (mmol/L) | 0.91 ± 0.56 | 1.22 ± 1.08 | 1.87 ± 1.60 | <0.0001 |
HDL (mmol/L) | 1.64 ± 0.33 | 1.41 ± 0.32 | 1.22 ± 0.25 | <0.0001 |
LDL (mmol/L) | 2.23 ± 0.66 | 2.71 ± 0.71 | 2.97 ± 0.72 | <0.0001 |
FBG (mmol/L) | 4.49 ± 0.46 | 4.77 ± 1.0 | 5.13 ± 1.34 | <0.0001 |
NEFA (μmol/dL) | 32.8 ± 8.58 (n = 10) | 40.8 ± 8.04 (n = 55) | 47.4 ± 7.86 (n = 36) | <0.0001 |
EPA (pg/mL) | 340.74 ± 200.51 (n = 10) | 363.95 ± 458.63 (n = 55) | 386.91 ± 309.30 (n = 36) | 0.1761 |
